Tolerability study of rhinothermy in healthy participants delivered by nasal high flow therapy (rNHF) at 41°Celsius and 45°Celsius

Fisher & Paykel Healthcare Limited0 个研究点目标入组 20 人开始时间: 2021年7月2日最近更新: 2022年11月28日

适应症

试验速览

暂无简介。

•Twenty healthy participants aged 18 to 75 years who are in the Investigator’s opinion, able and willing to comply with all study requirements.
•Two weeks post full vaccination against SARS-CoV-2 (COVID-19); may either be New Zealand based COMINARTY (Pfizer BioNTech) or administration of equivalent vaccination

•Upper respiratory tract infection (sore throat, cough, rhinorrhoea and/or fever (subjective of objective) within the last fourteen days
•Chronic respiratory illness currently being treated e.g. asthma
•Nasopharyngeal conditions such as a deviated septum and acute/chronic rhinitis, which the investigator considers could impair nasal breathing
•Use of nasal sprays within the last seven days
•Current smoker, defined as someone who has smoked or vaped within the last 28 days
•Current use of or requirement of oral antibiotics for a respiratory tract infection, pneumonia or infective exacerbation of an underlying respiratory condition
•Current use of or requirement of parenteral antibiotics
•Have an implantable medical device
•Have any other condition which, at the investigator’s discretion, is believed may present a safety risk to the participant or others, or impact the study results or the feasibility of the study.
•Previous enrolment in any trials investigating the use of rhinothermy.

发起方